syngeneic t lymphocytes

Cell therapyexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2014 (NCT02315118)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, passive

    immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • syngeneic t lymphocytes
  • t-cells rituximab + il-2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02315118Phase 1/Phase 2 (Phase 2)Dec 1, 2014National University of Singapore, Singapore General Hospital
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National University of SingaporeAcademic/Hospital1112014
Singapore General HospitalAcademic/Hospital1012014
2 organizations
Page 1 / 1